Department of Structural and Functional Biology, University of Campinas, Campinas, São Paulo, Brazil.
PLoS One. 2013 Jun 14;8(6):e65913. doi: 10.1371/journal.pone.0065913. Print 2013.
The modulation of inflammatory processes is a necessary step, mostly orchestrated by regulatory T (Treg) cells and suppressive Dendritic Cells (DCs), to prevent the development of deleterious responses and autoimmune diseases. Therapies that focused on adoptive transfer of Treg cells or their expansion in vivo achieved great success in controlling inflammation in several experimental models. Chloroquine (CQ), an anti-malarial drug, was shown to reduce inflammation, although the mechanisms are still obscure. In this context, we aimed to access whether chloroquine treatment alters the frequency of Treg cells and DCs in normal mice. In addition, the effects of the prophylactic and therapeutic treatment with CQ on Experimental Autoimmune Encephalomyelitis (EAE), an experimental model for human Multiple Sclerosis, was investigated as well.
METHODOLOGY/PRINCIPAL FINDINGS: EAE was induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein (MOG35-55) peptide. C57BL/6 mice were intraperitoneally treated with chloroquine. Results show that the CQ treatment provoked an increase in Treg cells frequency as well as a decrease in DCs. We next evaluated whether prophylactic CQ administration is capable of reducing the clinical and histopathological signs of EAE. Our results demonstrated that CQ-treated mice developed mild EAE compared to controls that was associated with lower infiltration of inflammatory cells in the central nervous system CNS) and increased frequency of Treg cells. Also, proliferation of MOG35-55-reactive T cells was significantly inhibited by chloroquine treatment. Similar results were observed when chloroquine was administrated after disease onset.
We show for the first time that CQ treatment promotes the expansion of Treg cells, corroborating previous reports indicating that chloroquine has immunomodulatory properties. Our results also show that CQ treatment suppress the inflammation in the CNS of EAE-inflicted mice, both in prophylactic and therapeutic approaches. We hypothesized that the increased number of regulatory T cells induced by the CQ treatment is involved in the reduction of the clinical signs of EAE.
炎症过程的调节是预防有害反应和自身免疫性疾病发展的必要步骤,主要由调节性 T(Treg)细胞和抑制性树突状细胞(DC)协调完成。专注于过继转移 Treg 细胞或在体内扩增它们的疗法在几种实验模型中控制炎症方面取得了巨大成功。氯喹(CQ)是一种抗疟药物,已被证明可减轻炎症,尽管其机制仍不清楚。在这种情况下,我们旨在确定 CQ 治疗是否会改变正常小鼠中 Treg 细胞和 DC 的频率。此外,还研究了 CQ 的预防性和治疗性治疗对实验性自身免疫性脑脊髓炎(EAE)的影响,EAE 是人类多发性硬化症的实验模型。
方法/主要发现:通过用髓鞘少突胶质细胞糖蛋白(MOG35-55)肽免疫接种诱导 C57BL/6 小鼠发生 EAE。C57BL/6 小鼠用氯喹腹腔内治疗。结果表明,CQ 处理会引起 Treg 细胞频率增加和 DC 减少。我们接下来评估了预防性 CQ 给药是否能够减轻 EAE 的临床和组织病理学体征。我们的结果表明,与对照组相比,CQ 处理的小鼠发生了轻度 EAE,这与中枢神经系统(CNS)中炎症细胞浸润减少和 Treg 细胞频率增加有关。此外,氯喹处理显著抑制了 MOG35-55 反应性 T 细胞的增殖。在疾病发作后给予氯喹时也观察到类似的结果。
我们首次表明 CQ 治疗可促进 Treg 细胞的扩增,这与先前表明氯喹具有免疫调节特性的报道一致。我们的结果还表明,CQ 治疗可抑制 EAE 小鼠 CNS 中的炎症,无论是在预防性还是治疗性方法中。我们假设 CQ 治疗诱导的调节性 T 细胞数量增加参与了 EAE 临床体征的减轻。